Breaking the Myth: Delayed Intensification Side Effects in Modern ALL Treatment (2025 Update) Check back later for a possible video summary. Videos are created for most articles. Introduction Delayed intensification therapy has long been a cornerstone in the treatment of pediatric acute lymphoblastic
Tag: acute lymphoblastic leukemia
Hidden First Signs of Leukemia That Doctors Often Miss in Primary Care
Carfilzomib Therapy in Pediatric Acute Lymphoblastic Leukemia
Carfilzomib Therapy in Pediatric Acute Lymphoblastic Leukemia Overview In this study, the safety and tolerability of a combination of carfilzomib and vincristine, dexamethasone, asparaginase, and daunorubicin (VXLD) were assessed in children with relapsed and/or refractory acute lymphoblastic leukemia (ALL). ALL is the most common cancer diagnosed in childhood and survival for patients
pediatric leukemia patients utilizing levofloxacin
pediatric leukemia patients utilizing levofloxacin STUDY BACKGROUND Bacterial infection-related morbidity and mortality are high in children treated for acute myeloid leukemia (AML) and relapsed acute lymphoblastic leukemia (rALL). Bacteremia not only contributes to mortality but also prolongs hospitalization, delays chemotherapy, decreases the quality of life, and requires the administration of costly and
